Zions Bancorporation National Association UT Trims Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

Zions Bancorporation National Association UT lessened its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 55.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 186 shares of the pharmaceutical company’s stock after selling 227 shares during the period. Zions Bancorporation National Association UT’s holdings in Vertex Pharmaceuticals were worth $83,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in VRTX. Activest Wealth Management bought a new stake in Vertex Pharmaceuticals during the first quarter valued at $25,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 45 shares during the last quarter. Access Investment Management LLC purchased a new stake in Vertex Pharmaceuticals during the second quarter valued at about $27,000. Flaharty Asset Management LLC purchased a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth about $32,000. Finally, Legacy Investment Solutions LLC purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at about $29,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $429.22 on Wednesday. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.68. The firm’s 50-day moving average price is $405.72 and its 200-day moving average price is $428.16. The company has a market capitalization of $108.90 billion, a PE ratio of 30.68 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter last year, the firm earned $4.38 earnings per share. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Cantor Fitzgerald decreased their price target on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 5th. HC Wainwright lowered their price objective on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating for the company in a research report on Tuesday, August 5th. Scotiabank lowered their price target on shares of Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a report on Tuesday, August 5th. JPMorgan Chase & Co. increased their target price on shares of Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. Finally, Canaccord Genuity Group dropped their price objective on Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating for the company in a report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $489.10.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.